CN109692225A - A kind of new application of Dabaidu Capsules - Google Patents

A kind of new application of Dabaidu Capsules Download PDF

Info

Publication number
CN109692225A
CN109692225A CN201710998950.1A CN201710998950A CN109692225A CN 109692225 A CN109692225 A CN 109692225A CN 201710998950 A CN201710998950 A CN 201710998950A CN 109692225 A CN109692225 A CN 109692225A
Authority
CN
China
Prior art keywords
dabaidu
capsules
cell
new application
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710998950.1A
Other languages
Chinese (zh)
Inventor
曹丽华
肖利辉
贺莲
张静
刘爱霞
刘娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanshou Kangyun Pharmaceutical Technology Co Ltd
Original Assignee
Hanshou Kangyun Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanshou Kangyun Pharmaceutical Technology Co Ltd filed Critical Hanshou Kangyun Pharmaceutical Technology Co Ltd
Priority to CN201710998950.1A priority Critical patent/CN109692225A/en
Publication of CN109692225A publication Critical patent/CN109692225A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/648—Myriapods, e.g. centipedes or millipedes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the new applications of Dabaidu Capsules, and in particular to the application in antitumor.The present invention has found through overtesting: Dabaidu Capsules can effectively inhibit the growth of the tumour cells such as breast cancer, cervical carcinoma, sdenocarcinoma of stomach, gastric cancer；Animal experiments show that Dabaidu Capsules can inhibit the growth of Implanted breast cancer in mouse, gastric cancer, new application for old medicine is provided fundamental basis, new approaches are provided to develop the antitumor action of Dabaidu Capsules, Dabaidu Capsules are to have listed Chinese patent drug, a series of clinical safety assessment is had already passed through, there is good potential applicability in clinical practice.

Description

A kind of new application of Dabaidu Capsules
Technical field
The present invention relates to the new applications of Dabaidu Capsules, and in particular to new application of the Dabaidu Capsules in anti-tumor aspect.
Background technique
Tumour is body under the effect of various tumorigenesis factors, and the cell of local organization loses at the genetic level grows it Normal regulation, lead to clonal abnormality hyperplasia and the neoformation that is formed.According to the biological characteristics of tumour and to the danger of body Evil property is different, is generally divided into benign tumour and malignant tumour two major classes.
Existing treatment means mainly have operation, chemotherapy etc., these methods have different degrees of side effect, grind with to tumour That studies carefully deepens continuously, and complex treatment and individualized treatment have become the main trend of oncotherapy.In recent years, traditional Chinese medicine is treated The clinical research of malignant tumour has penetrated into each stage of oncotherapy, and satisfactory effect is obtained in terms of Synergy and attenuation.
Dabaidu Capsules by rheum officinale, dandelion, dried orange peel, semen momordicae, the root of Dahurain angelica, radices trichosanthis, honeysuckle, Cortex Phellodendri, olibanum (system), The 17 taste Chinese medicines such as Radix Angelicae Sinensis, radix paeoniae rubra, dry toad (system), centipede, scorpio, snake slough (wine toast), saltcake and Radix Glycyrrhizae, the system to process from strand Agent.Function is the Toxin-Vanquishing that purifies the blood, swelling and pain relieving.It is scorchingly hot for internal organs, syphilis caused by blood is unclear, blood strangury, gonorrhoea, urethra thorn Bitterly, constipation, scabies, ulcer sores, congestion and swelling pain.Chinese medicine thinks that malignant tumour belongs to the models such as " accumulation ", " disliking swollen ", " pain " Farmland, the illness is mostly because of deficiency of vial QI, visceral dysfunction, so that cult poison is taken advantage of a weak point, accumulates and gathers in channels and collaterals, internal organs, is body yin Sun imbalance, qi and blood dysfunction, cause the evil retention of qi stagnation blood stasis, visitor, cult poison accumulation, accumulate it is strongly fragrant it is blocking caused by.Treatment has righting training Sheet, activating microcirculation and removing stasis medicinal, clearing heat and detoxicating, dispersing stagnated hepatoqi, resolving hard lump, dysmenorrhea is active, all therapeutic rules of combatting poison with poison.Dabaidu Capsules There is the effect of purifying the blood Toxin-Vanquishing, have the function of killing cancer cell, i.e., it is clearing heat and detoxicating, combat poison with poison, but side effect is again much Less than radiotherapy chemotherapy；Big Toxin-Vanquishing also has the effect of swelling and pain relieving simultaneously, can be used for the pain of cancer later period reduction of patient.
Dabaidu Capsules are had not yet to see for antitumor report.
Summary of the invention
The object of the present invention is to provide a kind of new applications of Dabaidu Capsules.
The present invention provides the applications of Dabaidu Capsules anti-tumor aspect.Dabaidu Capsules are the proliferation tools to tumour cell There is inhibiting effect.Specifically Dabaidu Capsules are that experiment in vitro is inhibited to the proliferation of tumour cell.
A kind of new application of Dabaidu Capsules of the present invention, experiment in vitro use mtt assay, the tumour cell include but It is not limited to breast cancer, cervical carcinoma, sdenocarcinoma of stomach, gastric cancer tumor cell.
Dabaidu Capsules of the present invention are Kamp Pharmaceuticals Co., Ltd.'s production.
The new application of Dabaidu Capsules provided by the invention has the advantage that
1, Fang Xie
Rheum officinale: heat and toxic materials clearing away, clearing heat-fire, removing pattogenic heat from the blood and toxic material from the body, by silt promoting menstruation, removing dampness through diuresis and removing jaundice.
Dandelion: clearing heat and detoxicating, dispersing swelling and dissipating binds, inducing diuresis for treating strangurtia.
Dried orange peel: regulating qi-flowing for strengthening spleen, eliminating dampness and eliminating phlegm.
Semen momordicae: mass dissipating and swelling eliminating attacks poison treatment sore.
The root of Dahurain angelica: relieving exterior syndrome and dispelling cold, wind-expelling pain-stopping, a surname clearing the nasal passage, eliminating dampness stops band, detumescence and apocenosis.
Radices trichosanthis: clearing heat-fire promotes the production of body fluid to quench thirst, detumescence and apocenosis.
Honeysuckle: clearing heat and detoxicating, dispelling wind and heat from the body.
Cortex Phellodendri: heat-clearing and damp-drying drug, purging intense heat, except steaming, detoxification sore treatment.
Olibanum (system): promoting blood circulation analgesic therapy, detumescence and promoting granulation.
Centipede: relieve the wind syndrome antispastic is removed obstruction in channels to relieve pain, dispersing swelling and dissipating binds.
Scorpio: relieve the wind syndrome antispastic is removed obstruction in channels to relieve pain, dispersing pathogen accumulation.
Snake slough (wine toast): wind-dispelling calms the frightened, moves back screen, removing toxic substances.
Saltcake: relieving constipation by purgation, moistening for dryness and softening hard mass, detumescence of relieving inflammation or internal heat.
Rheum officinale, dandelion, semen momordicae, honeysuckle, Cortex Phellodendri etc. have the effect of clearing heat and detoxicating in prescription, and all medicine collaborations are made With effect is more very.Centipede, scorpio dispersing pathogen accumulation, combat poison with poison.The root of Dahurain angelica cooperates olibanum (system) promoting blood circulation and stopping pain.
2, drug of the present invention, which resists, truly has curative effect in terms for the treatment of tumour, and toxic side effect is small.
3, there is analgesic efficacy, pain among cancer patients can be alleviated simultaneously in treatment, improve patients ' life quality.
4, through experiments, it was found that: Dabaidu Capsules can effectively inhibit breast cancer, cervical carcinoma, sdenocarcinoma of stomach, Growth of Gastric, together When mice-transplanted tumor can be inhibited to grow.
Specific embodiment
Following example is only to further illustrate the present invention, range that the invention is not limited in any way.
Experimental example 1: Dabaidu Capsules antitumor activity screening
1, experimental material
1.1 drugs and reagent: F12 culture medium (GIBCO), RPMI1640 culture medium (GIBCO), DMEM culture medium (GIBCO), Trypsase (Sigma), newborn bovine serum (GIBCO), MTT(Sigma), DMSO, (Kang Pu medicine company share is limited for Dabaidu Capsules Company, national drug standard Z20043195).
1.2 cell strain
A549(human lung carcinoma cell line), HepG2(human hepatoma cell strain), HL-60(human leukemia cell line) and MCF-7(human milk Adenocarcinoma cell strain), HeLa(human cervical carcinoma cell lines), SGC-7901(BGC823 cell line) and BGC-823(gastric carcinoma cells Strain) it is provided by Shanghai Pharmaceutical Inst., Chinese Academy of Sciences.
1.3 instrument
Superclean bench (Suzhou Chinese mugwort Kelin cleaning equipment Co., Ltd), constant temperature CO2Incubator (German Heraeus), it is enzyme-linked to exempt from Epidemic disease detector (U.S. BIO-RAD), inverted biologic microscope (Japanese OLYMPUS) and plate shaker (Jiangsu light laboratory apparatus Factory).
2, experimental method
2.1 prepare Dabaidu Capsules solution: after Dabaidu Capsules are first configured to the mother liquor of 0.1 M with DMSO, then it is dilute with culture medium It is interpreted into the working solution of 0.01 M, is then diluted to 5.0,2.5,1.25,0.625,0.3125 mM, six concentration for 2 times, wherein DMSO Respective concentration be 10%, 5%, 2.5%, 1.25%, 0.625% and 0.3125%.Positive control drug taxol is formulated as 0.1 with DMSO After the mother liquor of M, then it is diluted to culture medium the working solution of 0.01 M, is then diluted to 10 for 10 times3、102、10、1、10-1UM six A concentration.
2.2 mtt assay measure Dabaidu Capsules to human lung carcinoma cell (A549), human liver cancer cell (HepG2), human leukemia Cell strain (HL-60), Breast cancer lines (MCF-7), human cervical carcinoma cell lines (HeLa), BGC823 cell line (SGC- And the inhibiting effect of human stomach cancer cell line (BGC-823) 7901): suspension cell A549, HepG2 in logarithmic growth phase are taken, HL-60, MCF-7, HeLa, SGC-7901, BGC-823 cell strain, are added 0.05% tryptic digestive juice, and digestion makes adherent thin Born of the same parents fall off, and cell concentration is adjusted to 4.5 × 10496 well culture plates, 100 holes μ l/ are added in/ml.Set constant temperature CO2In incubator Culture 24 hours, changes liquid.Positive control drug is taxol, is dissolved with DMSO.Every hole is separately added into the sample of 1 μ l various concentration. Sample-adding group and control group are all provided with 3 multiple holes, and every block of plate is equipped with blank control group (only plus culture medium).The final concentration of sample is distinguished Be 100,50,25,12.5,6.25 and 3.125 μM, the final concentration of corresponding DMSO is respectively 0.1%, 0.05%, 0.025%, 0.0125%, 0.00625% and 0.003125%.Sample uses 0.1% DMSO as solvent control at 100 μM of final concentration, remaining Concentration makees negative control with culture medium.Final concentration of the 10 of positive control drug taxol2、10、1、10-1、10-2With 10-3μM。 Cell is at 37 DEG C, 5% CO2After being incubated for 48 h respectively in incubator, MTT(5 mg/ml, Sigma is added), 20 holes μ l/.Continue After cultivating 4 h, culture medium is discarded, 100 hole μ l/ DMSO is added, is shaken 5 minutes on plate shaker, uses enzyme-linked immunosorbent assay instrument The OD value in each hole is measured under 570 nm wavelength, and calculates cell inhibitory rate.
2.3 result processing method
The experiment of every plant of cell is repeated once above, carries out data processing with the result tested twice.
Cell survival rate=(the OD value of medicine feeding hole-blank control OD value)/(OD value-blank control OD of negative control hole Value)
The proliferation inhibition rate of cell=100%- cell survival rate
2.4 experimental results: as shown in table 1.
Table 1: half-inhibitory concentration (IC50/ μM) of the big Toxin-Vanquishing particle to various tumour cells
Cell category The Dabaidu Capsules IC that embodiment 1 provides50(μM) Taxol IC50(μM)
Human lung carcinoma cell (A549) 4.3 0.69
Human liver cancer cell (HepG2) 5.9 0.85
Human leukemia cell line (HL-60) 6.6 0.074
Breast cancer lines (MCF-7) 0.09 0.0031
Human cervical carcinoma cell lines (HeLa) 0.12 0.014
BGC823 cell line (SGC-7901) 0.32 0.022
Human stomach cancer cell line (BGC-823) 0.24 0.014
Table 1 is as the result is shown: the Dabaidu Capsules that embodiment 1 provides are to human lung carcinoma cell (A549), human liver cancer cell (HepG2), Human leukemia cell line (HL-60) shows the cytotoxic activity of moderate strength, to Breast cancer lines (MCF-7) He Rengong Neck cancer cell strain (HeLa) all has more very strong cytotoxic activity, thin to BGC823 cell line (SGC-7901) and human gastric cancer Born of the same parents' strain (BGC-823) all has stronger cytotoxic activity.
The result shows that: Dabaidu Capsules provided by the invention treatment tumour especially breast cancer, cervical carcinoma, sdenocarcinoma of stomach and Curative effect is truly had in terms of gastric cancer.
Experimental example 2: influence of the Dabaidu Capsules to mice transplanted tumor model
1, experimental material: Dabaidu Capsules (Kamp Pharmaceuticals Co., Ltd., national drug standard Z20043195),
Small white mouse.
2, experimental method
In mouse hypodermic inoculation breast cancer and human gastric cancer, start to be administered orally after inoculating 24 hours, control group and drug agent Amount group (50mg/kg, 100mg/kg), is administered daily 3 times by every group animal 10, after being administered continuously 5 days, is calculated by tumor weight, It the results are shown in Table 2 and table 3.
The inhibiting effect that 2 Dabaidu Capsules of table grow mouse breast cancer
Dosage (mg/kg) Changes of weight (g) Knurl weight (g) Inhibiting rate (%)
Control group - +9.64 3.49 -
Medicine group 1 50 +7.23 1.84 52.7
Medicine group 2 100 +4.05 1.35 61.3
The inhibiting effect that 3 Dabaidu Capsules of table grow Mouse Gastric Cancer
Dosage (mg/kg) Changes of weight (g) Knurl weight (g) Inhibiting rate (%)
Control group - +8.35 2.84 -
Medicine group 1 50 +6.70 1.62 42.9
Medicine group 2 100 +3.78 1.45 48.9
The result shows that Dabaidu Capsules can effectively inhibit the growth of two kinds of transplantable tumors.

Claims (4)

1. a kind of new application of Dabaidu Capsules, it is characterised in that application of the Dabaidu Capsules in antitumor.
2. a kind of new application of Dabaidu Capsules according to claim 1, which is characterized in that Dabaidu Capsules are thin to tumour The proliferation of born of the same parents is inhibited.
3. a kind of new application of Dabaidu Capsules according to claim 2, which is characterized in that Dabaidu Capsules are experiment in vitro It is inhibited to the proliferation of tumour cell.
4. a kind of new application of Dabaidu Capsules according to claim 2, which is characterized in that experiment in vitro uses mtt assay, The tumour cell includes but is not limited to breast cancer, cervical carcinoma, sdenocarcinoma of stomach, gastric cancer tumor cell.
CN201710998950.1A 2017-10-24 2017-10-24 A kind of new application of Dabaidu Capsules Pending CN109692225A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710998950.1A CN109692225A (en) 2017-10-24 2017-10-24 A kind of new application of Dabaidu Capsules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710998950.1A CN109692225A (en) 2017-10-24 2017-10-24 A kind of new application of Dabaidu Capsules

Publications (1)

Publication Number Publication Date
CN109692225A true CN109692225A (en) 2019-04-30

Family

ID=66226342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710998950.1A Pending CN109692225A (en) 2017-10-24 2017-10-24 A kind of new application of Dabaidu Capsules

Country Status (1)

Country Link
CN (1) CN109692225A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111481649A (en) * 2020-04-24 2020-08-04 重庆市中医院 External traditional Chinese medicine composition for treating breast cancer and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张青: "恶性肿瘤是否能吃大败毒胶囊_恶性肿瘤_百姓问医生", 《HTTPS://WWW.JIANKANG.COM/ASK/38859313.SHTML》 *
石凤晶等: "肾肿瘤患大败毒胶囊和穿王消炎胶囊一起吃吗_寻医问药网", 《HTTP://CLUB.XYWY.COM/QUESTION/20160215/125708030.HTM》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111481649A (en) * 2020-04-24 2020-08-04 重庆市中医院 External traditional Chinese medicine composition for treating breast cancer and preparation method thereof

Similar Documents

Publication Publication Date Title
CN103908473B (en) Treat and prevent the application of the nanometer silver anti-cancer composition of uterus neck cancer
CN106064993A (en) The culture medium of a kind of Hericium erinaceus (Bull. Ex Fr.) Pers., bioconversion mycelium, the mycelial extract of bioconversion and application thereof
CN108567820B (en) A Chinese medicinal composition for treating tumor, and its preparation method
CN104586873B (en) Application of the oroxin A in treating cancer medicine is prepared
CN101062029B (en) Application of wogonin in the preparing of medicine for treating gastric cancer
CN109692225A (en) A kind of new application of Dabaidu Capsules
CN102389559B (en) Traditional Chinese medicine composition and application as radiotherapy sensitizer
CN111658756A (en) Plaster for treating complications caused by malignant tumor and preparation method thereof
CN104857436B (en) Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application
CN106214740A (en) A kind of Chinese medicine composition and its production and use
CN113577187B (en) Traditional Chinese medicine composition and traditional Chinese medicine extract for treating influenza and preparation method and application thereof
CN113413402B (en) Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection disease
CN102755563A (en) Chinese medicinal composition for treating chronic prostatitis and preparation method thereof
CN101816762A (en) Medicinal preparation for treating colpitis and preparation method thereof
CN112245494A (en) External medicine for treating gout and preparation method thereof
CN105106337A (en) Thunder god vine medical wine for treating rheumatoid arthritis
CN104840748B (en) Chinese medicine composition with anti-cancer of the brain activity and its preparation method and application
CN104435931B (en) One kind analgesic patch and preparation method thereof
CN104887690B (en) Application of the chonglou saponin in antitumor drug is prepared
CN107184912A (en) The positive disperse accumulations compound preparation of one breeding and its application
CN109125427B (en) Penyanjing suppository and preparation method thereof
CN107669700A (en) A kind of medicine for treating ulcerative colitis and preparation method thereof
CN111494446B (en) Traditional Chinese medicine composition for treating biliary colic and application thereof
CN103083445A (en) Traditional Chinese medicine preparation used for treating skin ulcers, and preparation method thereof
CN107929344B (en) Lithospermum compound composition for preventing and treating laryngeal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190430